
Allogene Therapeutics, Inc. (NASDAQ:ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with multiple myeloma.
ALLO-605 is the next-generation AlloCAR T product candidate targeting BCMA currently being investigated in the phase 1 clinical study.